Global Acne Therapeutics Market Analysis

Global Acne Therapeutics Market Executive Summary

The skin condition known as acne develops when oil and dead skin cells clog the hair follicles. Even though it affects people of all ages, this condition is most prevalent in teenagers. Antibiotics, retinoids, and retinoid-like drugs are the most widely used medications. During the forecast period, one of the key factors boosting the product's demand Global is the rising prevalence of skin disorders.

Market Size and Key Findings

The Global Acne Therapeutics Market size is at around US $ xx Bn in 2021 and is projected to reach US $ xx Bn in 2030, exhibiting a CAGR of xx% during the forecast period.

Global Acne Therapeutics Market Size (In USD Bn)

(2021-2030F)

Market Dynamics

Market Growth Drivers Analysis

An increase in the prevalence of acne disorders worldwide is driving the growth of the market for acne medications. Two major factors influencing the market growth are teenagers' adoption of unhealthy lifestyles and the rising acceptance of skin care products. The demand for acne medication would also increase as a result of the accessibility and public awareness of a wide range of products containing antibiotic agents, such as lotions, creams, and gels, as well as the additional advantages linked to their use. Numerous factors, such as unhealthy lifestyles, poor diets, smoking, hormonal changes, and excessive sebum secretion, contribute to the rise in acne prevalence.

Market Restraints

Even though chronic acne is more common in the world, certain factors are preventing the market for acne treatments from expanding. One of them is a side effect of medications used to treat acne. The National Center for Biotechnology Information (NCBI) reports that the most typical side effects of antibiotics are nausea, vomiting, or diarrhea, which affect 7% of people taking tetracycline on average and 4% of people taking macrolides.

Competitive Landscape

Key Players

The prominent players operating in this market include Johnson & Johnson Services, Inc. (U.S.), Bayer AG (Germany), Allergan (Ireland), Valeant Pharmaceutical International, Inc. (U.S.), Botanix Pharmaceuticals (Australia), Pfizer Inc. (U.S.), GALDERMA (Switzerland), Bausch Health Companies Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel) and GlaxoSmithKline Plc. (U.K.)